Prevalence of potential drug-drug interactions among intensive care unit patients receiving linezolid: a cross-sectional study.
Eur Rev Med Pharmacol Sci
; 27(19): 9396-9400, 2023 Oct.
Article
in En
| MEDLINE
| ID: mdl-37843351
ABSTRACT
OBJECTIVE:
Linezolid is commonly used in intensive care units (ICU) but has the potential to interact with other drugs. This study aimed to evaluate the prevalence of potential drug-drug interactions in ICU patients receiving linezolid. PATIENTS ANDMETHODS:
Data of ICU patients receiving linezolid were extracted and included in the Hospital Prescription Analysis Program of China, and the risk of potential drug-drug interactions between concomitant drugs and linezolid was evaluated using the Lexicomp database.RESULTS:
A total of 3,712 ICU patients from 59 hospitals were included in the analysis, and patients received an average of 17 concomitant drugs. A total of 67.9% of patients had potential drug-drug interactions. Patients receiving concomitant drugs with risk ratings of "X", "D", and "C" categories were 20.8%, 30.4%, and 35.1%, respectively. Opioids were the most frequently prescribed drug class with drug-drug interactions (DDIs) in the "X" category, whereas butorphanol, metoclopramide, and sufentanil were the most contraindicated concomitant drugs.CONCLUSIONS:
ICU patients receiving linezolid have a high prevalence of potential drug-drug interactions, and efforts should be made to better recognize and manage this risk.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Intensive Care Units
Limits:
Humans
Language:
En
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
FARMACOLOGIA
/
TOXICOLOGIA
Year:
2023
Document type:
Article
Affiliation country:
China